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Background: Monitoring progress toward global treatment targets using HIV
programme data in sub-Saharan Africa has proved challenging. Constraints in routine
data collection and reporting can lead to biased estimates of treatment outcomes. In
2010, South Africa introduced an electronic patient monitoring system for HIV patient
visits, TIER.Net. We compare treatment status and outcomes recorded in TIER.Net to
outcomes ascertained through detailed record review and tracing in order to assess
discrepancies and biases in retention and mortality rates.
Methods: The Agincourt Health and Demographic Surveillance System (HDSS) in
north-eastern South Africa is served by eight public primary healthcare facilities. Since
2014, HIV patient visits are logged electronically at these clinics, with patient records
individually linked to their HDSS record. These data were used to generate a list of
patients >90 days late for their last scheduled clinic visit and deemed lost to follow-up
(LTFU). Patient outcomes were ascertained through a review of the TIER.Net database,
physical patient files, registers kept by two non-government organizations that assist with
patient tracing, cross-referencing with the HDSS records and supplementary physical
tracing. Descriptive statistics were used to compare patient outcomes reported in
TIER.Net to their outcome ascertained in the study.
Results: Of 1,074 patients that were eligible for this analysis, TIER.Net classified 533
(49.6%) as LTFU, 80 (7.4%) as deceased, and 186 (17.3%) as transferred out. TIER.Net
misclassified 36% of patient outcomes, overestimating LTFU and underestimating
mortality and transfers out. TIER.Net missed 40% of deaths and 43% of transfers out.
Patients categorized as LTFU in TIER.Net were more likely to be misclassified than
patients classified as deceased or transferred out.
Discussion: Misclassification of patient outcomes in TIER.Net has consequences for
programme forecasting, monitoring and evaluation. Undocumented transfers accounted
for the majority of misclassification, suggesting that the transfer process between clinics
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should be improved for more accurate reporting of patient outcomes. Processes that lead
to correct classification of patient status including patient tracing should be strengthened.
Clinics could cross-check all available data sources before classifying patients as LTFU.
Programme evaluators and modelers could consider using correction factors to improve
estimates of outcomes from TIER.Net.
Keywords: HIV, retention in care, bias, South Africa, health information systems
INTRODUCTION
At the end of 2017, it was estimated that there were 36.9 million
people living with HIV (PLHIV) worldwide, with 70% of the
disease burden situated in sub-Saharan Africa (1, 2). The World
Health Organization’s (WHO) revised HIV treatment guidelines
in 2015 call for immediate provision of lifelong antiretroviral
therapy (ART) to all people testing positive for HIV. By the end
of 2017, 60% of PLHIV in sub-Saharan Africa were on ART
(1, 2). Whilst ART initiation rates have been increasing over
time, in order to reduce HIV transmission rates and achieve 90-
90-90 AIDS elimination goals, there is a need for accelerated
increases in treatment adherence and retention in care (3–5).
South Africa has the largest population of PLHIV worldwide,
with an estimated 18.8% of the adult population aged 15–49 years
old living with HIV, representing 7.2 million people (1, 2). By the
end of 2018, an estimated 68% of PLHIV in South Africa were on
ART (1, 2).
The rapid growth in access to ART has accentuated the
need for an affordable and accurate way to monitor and
evaluate treatment programmes (6–8), including documenting
the number of people alive and on treatment, and programme
impact on mortality. In the past, the progress of patients on ART
was mainly monitored through patient cohorts (9) and tallying
numbers of services rendered to inform resource allocation (8).
However, evaluation of HIV programmes has proved challenging
due to multiple data constraints. These include concerns about
data reliability (8), and continued use of paper registers which
often lack unique identifiers, suffer from incompleteness (10),
and are cumbersome to use with increasing patient numbers
and length of patient follow-up (11, 12). Another major concern
is “silent transfers” whereby patients change clinics informally
and without accompanying documentation, a phenomenon
which has become more prevalent with the expansion of ART
programmes (13, 14). As a result, there is concern that many
high-burden countries are ill-equipped to report on the outcomes
of patients in care and on treatment (6, 7, 15–17).
In order to address these concerns, many countries are
scaling-up the use of electronic patient registers (11). However,
challenges persist including insufficient linkages between clinics
(10), insufficient training of staff who are responsible for
entering this information (10), and staff shortages (18–21),
resulting in some staff responsible for data management being
stretched across multiple roles (22). This sometimes leads to
poor workflow, and staff resistance which results in poor
change management. Privacy and security issues (22) are also a
major concern.
In 2010, South Africa adopted TIER.Net, a three-tiered
monitoring approach involving paper registers (TIER 1—
recommended for facilities with <500 patients), an offline
electronic register (TIER 2—recommended for facilities with
500–2,000 patients) and networked electronic medical records
(TIER 3—recommended for facilities with more than 2,000
patients) (11). This allowed for different tiers to be implemented
in each facility based on the context and resources available
at the time of implementation and typically involved a phased
evolution, beginning with preparation for TIER.Net, installation
and training, back capturing, live capturing and finally a live site
able to produce monthly and quarterly reports with staff on-site
to manage it. In 2014, an estimated 3,000 out of 4,000 public
sector clinics in South Africa were using TIER.Net (23, 24) in one
of the three phases of implementation. As of 2017, TIER 3 was
still in its pilot phase (25).
ART patient outcomes have evolved since the start of national
HIV treatment programmes. In several cohort studies of ART
programmes in sub-Saharan Africa, there have been reports of
higher rates of LTFU among patients who initiated ART in later
years compared to earlier years (26–28). This may be explained
by patients increasingly initiating treatment while less severely
ill (29), as well as a negative consequence of patient numbers
increasing such as facility workloads (30), raising concerns about
the sustainability of these programmes. Some systematic reviews
have shown that the percentage of patients LTFU who have
died has decreased in later years as eligibility criteria have
evolved to include less immunologically compromised patients,
and as the proportion of patients LTFU has increased (13, 31).
Furthermore, scale-up and decentralization of these programmes
means ART can be offered at clinics closer to patients’ homes,
which may serve as an incentive to self-transfer in order to
continue treatment at more convenient locations (13, 32).
Unpublished TIER.Net analyses from 2018 showed LTFU
rates to range from 11 to 15% in the first three months and from
27 to 34% in the first year of ART (Y.Pillay, HIV Think-tank
update, March 19, 2019). The high percentages of LTFU present
many issues. Firstly, if these patients have really stopped ART
then they have a higher mortality risk (33–35), and are more
likely to transmit HIV (36–39). Given that patients that are LTFU
have poorer outcomes, LTFU can also through misclassification
bias event rates such as mortality downwards (40), leading to
biased performance indicators for ART programmes. Accurate
mortality rates are also important as they are used as parameters
for projections such as in theUNAIDS spectrum package (41, 42).
We compare patient outcomes recorded in TIER.Net to the
outcomes ascertained through a record review and tracing study
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for patients deemed lost to follow-up in eight public sector health
facilities in rural north-eastern South Africa. We aimed to assess
misreporting in TIER.Net and potential biases in the national
programme statistics reported from the TIER.Net database.
METHODS
Setting
The Agincourt Health and Demographic Surveillance System
(Agincourt HDSS) is located in rural north-eastern South
Africa, in Mpumalanga province which has the second highest
prevalence of HIV at 14.1% (43). HIV prevalence among people
15 years of age or older in the HDSS was estimated at 19.4% in
2010 (44). The Agincourt HDSS comprises of 31 villages covering
an area of 475 square kilometers with an estimated population of
115,000 people (45, 46).
There are five primary health facilities and three secondary
community health centers located within the Agincourt HDSS.
Every HIV-positive patient has a clinical file that is opened
when they first register at an ART clinic and updated at each
clinic visit. Following the clinic visit, visit-level information from
the patient file is entered into the national electronic database,
TIER.Net. All health facilities routinely trace patients that are
late for a scheduled clinic appointment. This tracing is done in
conjunction with two non-profit organizations, Right to Care
(RtC) and Home-Based Carers (HBC). Clinic staff must contact
all patients first by phone and if this does not yield a satisfactory
outcome, a home visit is organized. Patients are classified as lost
to follow-up (LTFU) if they have not returned 90 days after their
scheduled visit.
Demographic Surveillance
Data collection aims to capture all demographic events for the
Agincourt HDSS population. Fertility, mortality and migration
data are based on a comprehensive household registration system
that has been in operation since 1992. Following the baseline
demographic surveillance survey in 1992 and three update
rounds until 1998, the site has conducted annual surveys since
1999 (45, 47–49). Trained fieldworkers visit each household and
interview the most knowledgeable adult available. During the
visit, individual-level information on all household members is
checked and updated and any events that have occurred since
the last census round are recorded. Starting in 2017, data have
been collected utilizing an electronic data collection system using
tablets (50).
Point-of-Contact Interactive Record Linkage (PIRL)
A key element of the data infrastructure for this study consists
of HIV patient visit logs collected by a study fieldworker in the
health facilities that provide ART in the area. This work started
in April 2014 at seven government facilities and was extended
in 2016 to include one additional health facility. In addition to
logging patient visits, these records are linked to the Agincourt
HDSS using a procedure that we have previously described as
Point-of-Contact Interactive Record Linkage (PIRL) (51, 52).
In brief, a fieldworker conducts a short uptake interview with
patients in the waiting area of the clinic. Patients who consent
are asked to declare a few personal identifiers that are used to
search a local copy of the Agincourt HDSS database using a
probabilistic algorithm. Matches are confirmed in interaction
with the patients, and the names of other household members are
used as a key attribute to adjudicate between possible matches.
Record Review and Tracing Study
Through the PIRL database, we identified patients who were
more than 90 days late for a scheduled clinic appointment from
HIV services on August 15, 2017 (the date of data extraction) at
any of the eight health facilities located in the Agincourt HDSS
area. These patients were recruited into a cohort and followed up
to ascertain their treatment and vital status i.e., whether they were
still alive.
All PLHIV aged 18 years or over, who had ever declared
residency in Agincourt HDSS, and had enrolled in the HIV
treatment and care programme since 2014 (after the Agincourt
HDSS record linkage was established at the health facilities) were
eligible for inclusion in the study.
Trained and supervised fieldworkers conducted a thorough
record review, comparing the list of patients LTFU against (a)
TIER.Net (b) patient clinic files, and (c) logbooks kept by the
RtC and the HBC. The PIRL database was also reviewed for
duplicate patients (different clinical records linking to the same
individual in the Agincourt HDSS database, which was taken as
evidence of silent transfers), and residency and vital status were
extracted from the Agincourt HDSS database. This was done on
a case-by-case basis.
HBC conducted a visit to the households of all patients
for whom a definitive outcome (defined as death, transfer out,
stopped ART, migrated, re-engaged in care, and alive with ART
status unknown) could not be established, or for whom routine
patient tracing was not done. Finally, all patients who remained
LTFU after the HBC visit, were searched for in TIER.Net
databases at clinics in close proximity to their home residence to
capture any further silent transfers.
We also reviewed the records for a stratified random sample of
162 patient records who were not LTFU as of August 15, 2017, in
order to assess whether TIER.Net misclassified any patients that
were still in care. This sample was chosen to include 18 patients
from every clinic (six men, six non-pregnant women, and six
women who initiated ART while pregnant) with the exception
of one clinic which had recently merged with another, and from
which we sampled 18 patients who had enrolled whilst in each of
the clinics prior to the merger.
Definitions
Definitions of terms used in this article are provided in Table 1.
Statistical Analyses
For patients included in the record review and tracing study,
we calculated counts and proportions for socio-demographic
and baseline clinical characteristics, TIER.Net treatment status,
the final outcome, and cross-tabulated TIER.Net status and the
final outcome.
To assess the degree and direction of mis-reporting of
patient outcomes in TIER.Net, we graphically present TIER.Net
treatment status and the final outcome proportions by some
selected patient characteristics. A Pearson’s chi-square test was
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TABLE 1 | Definitions of terms used.
Term Definition
The last appointment The last scheduled appointment for each patient as of August 15, 2017, when we generated the list of patients deemed LTFU.
TIER.Net treatment status The treatment status of the patient as recorded in TIER.Net during the comprehensive record review.
The final outcome The outcome ascertained for each patient through the record review and tracing process.
Data error A situation in which a patient was found still in care and <90 days late for their last appointment. Some data errors occurred because
visit dates had not been properly entered in the PIRL database. Patients categorized as a data error were excluded from our analyses.
Re-engagement A patient was considered to have re-engaged in care if they were found to be still in care at the same clinic where they initiated
treatment but were >90 days late for their last appointment (had been LTFU).
Transfer out A patient was considered to have transferred if they had either reported taking treatment at another clinic (for clinics outside the
Agincourt HDSS), if their ART initiation clinic had communicated with and ascertained their transfer to another clinic, or if there was
record of them collecting treatment at another clinic within the Agincourt HDSS.
Migration A patient was classified as having migrated out of the study site if they were recorded as having migrated through the Agincourt
HDSS demographic surveillance, this migration event happened after their last clinic visit date and there was no proof that they were
taking treatment at another facility.
Alive and not on ART A patient was considered alive and not on ART if they had been found and had said they had stopped ART, denied their HIV status or
refused to return to the clinic.
Alive with ART status unknown A patient was considered alive with ART status unknown if they were found to still be alive through the most recent Agincourt HDSS
demographic surveillance, with a surveillance date after their last clinic visit and there was no proof that they were taking treatment at
any facility.
used to compare whether TIER.Net treatment status and the final
outcome varied by all the categorical variables. We also present a
cross-tabulation of patient outcomes from the two sources.
A binary outcome variable was created to indicate whether
TIER.Net had misclassified a patient’s treatment status, with a
second outcome created to identify whether the patient was
recorded as LTFU in TIER.Net. All cases where an electronic
record could not be found were removed from further analysis.
To explore factors associated with misclassification in
TIER.Net, we ran bi-variate analyses with patient-level treatment
characteristics, demographic characteristics and facility-level
characteristics. All variables with p < 0.1 were included in the
multivariable logistic regression model. A parsimonious model
was achieved usingWald tests. This same procedure was followed
in order to understand what factors were associated with being
reported LTFU in TIER.Net. All analyses were conducted in Stata
15 (53) and all data visualization was done using R (54).
Ethics
Ethical approval was obtained from the London School of
Hygiene and TropicalMedicine, the University of Witwatersrand
and the Mpumalanga Department of health.
RESULTS
Database Population Characteristics
Over the study period, 4,089 patients were added to the PIRL
database and met the inclusion criteria. Of these 4,089, 1,325
(32.4%) met the LTFU criteria and were eligible for inclusion into
the record review and tracing study. Of these 1,325 patients, 166
(12.5%) did not have an ART initiation date and were assumed
to be pre-ART. Further investigation of these 166 patients found
46 (27.7%) had initiated ART after record linkage, 59 (35.5%)
were genuine pre-ART patients and 61 (36.7%) had initiated ART
before record linkage began. These 61 patients were excluded
from further analyses. Of the remaining 1,264 patients, 190
(15.0%) were found to have data errors (mostly due to missing
clinic visits in the PIRL database) and were excluded from further
analysis (Supplementary Figure 1).
Of 1,074 remaining patients, 280 (26.1%) initiated ART
for prevention of mother-to-child transmission (PMTCT), 737
(68.6%) met the ART initiation criteria for non-pregnant adults,
and 57 (5.3%) had not initiated ART yet (pre-ART).
Thirteen (8.0%) of the 162 patients still in care were excluded
from the analysis because they had not declared residency in the
HDSS. The remaining 149 from the random sample of patients
still in care were also assessed to see if misclassification also
occurred for those who remained engaged in care (Table 2).
TIER.Net Treatment Status
Of the 1,074 patients who remained eligible for this analysis, 533
(49.6%) were categorized as LTFU, 222 (20.7%) as still in care, 186
(17.3%) as transferred out, 80 (7.5%) as deceased, and 53 (4.9%)
could not be found in the TIER.Net database (Table 2).
There was a statistically significant difference (all p < 0.001)
in the TIER.Net treatment status by sex, age, ART initiation
status and reason, year of ART initiation, baseline CD4 count,
time on ART, clinic visit schedule, health facility, and time since
a missed appointment (see Supplementary Figure 2). Women
who initiated ART for PMTCT were less likely to be categorized
as deceased and more likely to be LTFU. All 149 patients
sampled as still in care were also reported as still in care
in TIER.Net.
Outcomes After Record Review and
Tracing Study
Of the 1,074 patients who remained eligible for this analysis, 326
(30.3%) were found to have transferred to another clinic, 234
(21.8%) to have re-engaged in care, 132 (12.3%) were deceased,
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TABLE 2 | Database population characteristics.
Not in
sample
Sample
Still in care Still in care LTFU Data error
2,615 149 1,074 190
N (%) N (%) N (%) N (%)
SEX
Female 2,016 (77.1) 94 (63.1) 807 (75.1) 147 (77.4)
Male 599 (22.9) 55 (36.9) 266 (24.8) 42 (22.1)
Missing 0 (0) 0 (0) 1 (0.1) 1 (0.5)
AGE
18–29 559 (21.4) 18 (12.1) 350 (32.6) 39 (20.5)
30–44 1,298 (49.6) 76 (51.0) 509 (47.4) 102 (53.7)
45–59 544 (20.8) 36 (24.2) 152 (14.1) 38 (20.0)
60+ 212 (8.1) 19 (12.7) 60 (5.6) 10 (5.3)
Missing 2 (0.1) 0 (0) 3 (0.3) 1 (0.5)
ART REASON
Non-PMTCT
women
1,533 (58.6) 54 (36.2) 487 (45.3) 101 (53.1)
PMTCT women 431 (16.5) 40 (26.9) 280 (26.1) 45 (23.7)
Men 598 (22.9) 55 (36.9) 250 (23.3) 42 (22.1)
Pre-ART 0 (0) 0 (0) 57 (5.3) 2 (1.1)
Missing 53 (2.0) 0 (0) 0 (0) 0 (0)
ART START YEAR
2014 320 (12.2) 62 (41.6) 211 (19.6) 41 (21.6)
2015 773 (29.6) 42 (28.2) 414 (38.6) 84 (44.2)
2016 951 (36.4) 32 (21.5) 350 (32.6) 54 (28.4)
2017 571 (21.8) 13 (8.7) 42 (3.9) 9 (4.7)
Missing 0 (0) 0 (0) 57 (5.3) 2 (1.1)
Time ON ART
≤3 months 190 (7.3) 10 (6.7) 325 (30.3) 15 (7.9)
3–6 months 260 (9.9) 2 (1.3) 190 (17.7) 9 (4.7)
6–12 months 560 (21.4) 23 (15.4) 228 (21.2) 41 (21.6)
12–24 months 842 (32.2) 40 (26.8) 219 (20.4) 75 (39.5)
>24 months 763 (29.2) 74 (49.7) 55 (5.1) 48 (25.3)
Missing 0 (0) 0 (0) 57 (5.3) 2 (1.1)
BASELINE CD4
<100 468 (17.9) 25 (16.8) 220 (20.5) 20 (10.5)
100–199 476 (18.2) 18 (12.1) 193 (18.0) 37 (19.5)
200–349 656 (25.1) 40 (26.9) 267 (24.9) 50 (26.3)
350–499 464 (17.7) 34 (22.8) 198 (18.4) 50 (26.3)
500+ 455 (17.4) 30 920.1) 164 (15.3) 33 (17.4)
Missing 96 (3.7) 2 (1.3) 32 (3.0) 0 (0)
REFILL SCHEDULE
1 month 1,056 (40.4) 38 (25.5) 714 (66.5) 72 (37.9)
2 months 1,016 (38.8) 77 (33.7) 240 (22.3) 64 (33.7)
3 months 314 (12.0) 26 (17.4) 86 (8.0) 17 (8.9)
>3 months 229 (8.8) 8 (5.4) 34 (3.2) 37 (19.5)
HEALTH FACILITY
Agincourt 540 (20.6) 18 (12.1) 282 (26.3) 160 (84.2)
Belfast 379 (14.5) 16 (10.7) 191 (17.8) 2 (1.0)
Cunningmore 227 (8.7) 15 (10.1) 74 (6.9) 0 (0)
Justicia 284 (10.9) 18 (12.1) 122 (11.4) 3 (1.6)
(Continued)
TABLE 2 | Continued
Not in
sample
Sample
Still in care Still in care LTFU Data error
2,615 149 1,074 190
N (%) N (%) N (%) N (%)
Kildare 462 (17.7) 18 (12.1) 120 (11.1) 6 (3.2)
Lillydale/Bhubezi 487 (18.6) 35 (23.5) 181 (16.8) 11 (5.8)
Thulamahashe 89 (3.4) 14 (9.4) 27 (2.5) 8 (4.2)
Xanthia 147 (5.6) 15 (10.1) 77 (7.2) 0 (0)
AGINCOURT HDSS OUTCOME
Still in HDSS 1,827 (69.9) 107 (71.8) 530 (49.3) 122 (64.2)
Deceased 2 (0.1) 0 (0) 83 (7.7) 1 (0.5)
Migrated 503 (19.2) 37 (24.8) 282 (26.3) 56 (29.5)
Not linked 283 (10.8) 5 (3.4) 179 (16.7) 11 (5.8)
TIME SINCE LAST APPOINTMENT
≤1 year – – 539 (50.2) –
1–2 years – – 392 (36.5) –
>2 years – – 143 (13.3) –
Not in sample: All patients eligible for the study but not LTFU in the PIRL database and
not included in the still in care sample; Sample: All patients included in the study (149 still
in care, 1,264 LTFU = 1 074 really LTFU + 190 data errors); Data error: Patients included
as LTFU but found to be still in care and <90 days late for their last appointment; For ART
start year data from 2017 reflects number of ART initiations up to mid-August when data
extraction occurred.
TABLE 3 | A cross-tabulation of TIER.Net treatment status and the final outcome.
TIER.Net status
Deceased Lost to
follow-up
Not
found
Still in
care
Transferred
out
Total
Final
Outcome
N (%) N (%) N (%) N (%) N (%) N (%)
LTFU 0 (0) 112 (21.0) 9 (17.0) 10 (4.5) 0 (0) 131 (12.2)
Deceased 80 (100) 38 (7.1) 8 (15.1) 6 (2.7) 0 (0) 132 (12.3)
Alive/Not
on ART
0 (0) 70 (13.1) 3 (5.7) 8 (3.6) 0 (0) 81 (7.5)
Migrated 0 (0) 47 (8.8) 5 (9.4) 1 (0.5) 0 (0) 53 (4.9)
Transferred 0 (0) 116 (21.8) 8 (15.1) 16 (7.2) 186 (100) 326 (30.4)
Re-
engaged
0 (0) 56 (10.5) 9 (17.0) 169 (76.1) 0 (0) 234 (21.8)
Alive/ART
unknown
0 (0) 94 (17.6) 11 (20.8) 12 (5.4) 0 (0) 117 (10.9)
Total 80 533 53 222 186 1074
117 (10.9%) were alive with ART status unknown, 81 (7.5%)
were alive but not on treatment, 53 (4.9%) had migrated to
another place of residence, and 131 (12.2%) were still LTFU
(Table 3). These outcomes differed (all p < 0.001) by sex, age,
ART initiation status and reason, baseline CD4 count, time on
ART, clinic visit schedule, health facility, whether the patient
record was successfully linked to an Agincourt HDSS record,
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FIGURE 1 | Outcome ascertained through record review and tracing stratified by (A) ART initiation status and (B) time since the last appointment.
and time since a missed appointment (some selected variables
illustrated in Figure 1).
Differences Between TIER.Net Treatment
Status and Final Outcomes
Records of deceased or transferred out patients documented
in TIER.Net aligned with patients’ final outcome (i.e., no
inaccuracies found for these two statuses). However, TIER.Net
misclassified 52 (39.4%) of 132 deaths. Of these 52, 38 (73.1%)
were classified as LTFU, 6 (11.5%) as still in care, and 8 (15.4%)
were not found in the system at all.
TIER.Net also misclassified 53 patients as still in care. Of
these, 10 (18.9%) were found to be LTFU, 16 (30.2%) to have
transferred, 12 (22.6%) as alive with unknown ART status, 8
(15.1%) alive but not on treatment, 6 (11.3%) to have died, and 1
(1.9%) to have migrated to another place of residence. TIER.Net
correctly captured 186 (57.1%) of 326 transfers.
Of 533 patients classified as LTFU by TIER.Net, 116 (21.8%)
were found to have transferred to another clinic, 70 (13.1%) to be
alive but not on treatment, 47 (8.8%) to have migrated to another
place of residence, 38 (7.1%) to have died, and 56 (10.5%) to have
re-engaged in care (38 of whom were resolved by new visit data
in the PIRL database and so it is possible that their TIER.Net
status could have also changed back to still in care) (Figure 2 and
Supplementary Figure 3).
As patients classified as LTFU in TIER.Net were more likely
to be misclassified we report on the factors associated with
being classified as LTFU in TIER.Net (Supplementary Data and
Supplementary Table 1).
Factors Associated With Misclassification
In the multivariable model (Table 4), men (OR: 1.47, p =
0.021) had higher odds of misclassification when compared to
women who initiated ART for non-PMTCT reasons (CD4,WHO
stage, tuberculosis coinfection). Higher baseline CD4 (CD4 100-
199 OR: 1.95. p = 0.002, CD4 ≥ 500 OR: 1.81, p = 0.014)
was also associated with higher odds of misclassification when
compared to patients who initiated treatment with CD4 < 100.
Health facility also remained statistically significant suggesting
that facility level variability plays a role in misclassification.
Patients who were linked to an Agincourt HDSS record in the
PIRL database (OR: 2.09, p < 0.001) were more likely to be
misclassified. Finally, patients who were between 1 and 2 years
late (OR: 1.62, p = 0.001) were more likely to be misclassified.
Older age (30–44 years OR: 0.73, p= 0.046, 45–59 years OR: 0.63,
p = 0.046) was associated with lower odds of misclassification
and patients on longer refill schedules (>3 months OR: 0.31, p=
0.009) were less likely to be misclassified.
DISCUSSION
In this paper, we described the discrepancies between the
treatment, vital and residency status of HIV patients enrolled in
care between April 2014 andAugust 2017 in a rural South African
setting as recorded in the national treatment database (TIER.Net)
and their treatment outcome following a comprehensive record
review and tracing study.
We found that TIER.Net misclassified 36% of the patient
outcomes. ART initiation reason, baseline CD4, health facility
attended, PIRL linkage, time since the last appointment, age, and
ART refill schedule were all found to be significantly associated
with misclassification. TIER.Net underestimated mortality and
overestimated the number of patients who were LTFU. Seventy-
nine percent of patients classified as LTFU in TIER.Net had a
final outcome ascertained, mirroring findings from a systematic
review of low and middle income country ART programmes
which found that tracing generated higher estimates of mortality
and lower estimates of LTFU (55). Our findings show that LTFU
is still an important problem in ART programmes in this setting,
even with routine patient tracing in place. TIER.Net also missed
43% of transfers with these silent transfers being the biggest
contributor to misclassification among those documented as
LTFU. We also found that 21.8% of patients had re-engaged in
care, a phenomenon that was previously not well understood,
but which is now increasingly recognized as becoming a
common feature of ART programmes (55). Using our findings to
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FIGURE 2 | Outcome ascertained through record review and tracing stratified by each TIER.Net status. A deceased or transferred status in TIER.Net is accurate.
Inaccuracies in the LTFU and still in care categories. Some patients categorized as still in care are LTFU, not currently on treatment, transfers out or dead.
revise LTFU figures to reflect re-engagement may help improve
programme evaluation and forecasting.
In our study, we found that 40% of deaths were missed by
TIER.Net, indicating that mortality of ART patients would be
underestimated if relying on this data source. Given the role that
national statistics play in HIV/AIDS projections (41, 42, 56), our
findings suggest a need for correction factors for the estimates
of the effect of ART on mortality. Although South Africa has a
good vital registration system in place (57), these data are not
currently linked to clinic-based information. However, with the
move to registering patient national ID numbers, clinics should
consider matching patients that are LTFU to the national death
registry and other available databases such as the national health
laboratory services database to ascertain vital status as this has
proved useful in other studies in South Africa (58–60). Clinics
in the Agincourt HDSS study area and other HDSS sites could
also consider using vital status data from annual demographic
surveillance to ascertain vital status for all patients.
The number of patient transfers to another clinic that were
missed in TIER.Net suggests that communication between clinics
is sub-optimal and that the current system for transferring
patients between clinics can be improved. With studies reporting
patient fear and concern about provider reactions if they return
to care after a treatment interruption (61, 62) it is possible
that some patients considered it less stressful to self-transfer or
restart treatment at another nearby clinic, rather than returning
to the facility where they had initiated treatment. These silent
transfers could lead to double counting of patients currently
on treatment, the second of the 90-90-90 targets, potentially
suggesting that the programme is performing better than it is.
Furthermore, given that the national treatment programme relies
on data from TIER.Net to plan and procure ART based on
active patient numbers, misclassification in the database, and
more specifically double-counting due to silent transfers may
lead to inaccurate drug forecasts and misestimation of medicines
and other commodities at the national level. This bias will only
increase as the South African ART programme expands with
more patients potentially moving into new clinics closer to their
homes and more people initiate ART with the move to test and
treat. Future work will consider how application of correction
factors from this researchwould change programme statistics and
drug forecasts.
It is also important to consider the risk that silent transfers
pose with regards to drug resistance, as this misclassifies
treatment experienced patients as treatment naïve and may
lead to patients being offered regimens that have lost their
optimal therapeutic benefit. This is particularly concerning
because resistance testing is not commonly used in these settings,
and can potentially lead to increases in levels of transmitted
drug resistance (63). Better referral systems, patient education,
regular information exchange between clinics, and provider
training (64), could improve recording of transfers and clinic
staff attitudes toward less adherent patients. The WHO also
recommends enforcement of unique identifiers as paramount to
improve patient safety, improve the efficient use of programme
resources by reducing duplications, and to improve programme
monitoring and evaluation (65). With national IDs becoming
mandatory at clinic registration, information exchange could
prove useful in identifying silent transfers. This should also
become less of an issue when TIER.Net is upgraded to a fully
networked database.
We found several factors to be associated with
misclassification of outcome in TIER.Net, with older age
and longer ART refill schedules found to be protective factors.
Older patients were less likely to be classified as LTFU in
TIER.Net which probably explains why they were subsequently
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TABLE 4 | Factors associated with TIER.Net misclassification.
cOR (95%CI) p-value aOR (95% CI)
(n = 1,074)
p-value
SEX
Female Reference
Male 1.08 (0.82–1.43) 0.584
AGE
18–29 Reference
30–44 0.81 (0.62–1.07) 0.141 0.73 (0.54–0.99) 0.046
45–59 0.62 (0.41–0.92) 0.017 0.63 (0.40–0.98) 0.041
60+ 0.72 (0.40–1.27) 0.253 0.70 (0.37–1.33) 0.279
ART REASON
Non-PMTCT women Reference Reference
Pregnant women 1.64 (1.22–2.20) 0.001 1.28 (0.92–1.78) 0.142
Men 1.34 (0.98–1.82) 0.063 1.47 (1.06–2.06) 0.021
Pre-ART 1.69 (0.83–3.47) 0.149 1.26 (0.57–2.78) 0.568
ART START YEAR
2014 Reference
2015 1.11 (0.79–1.54) 0.556
2016 1.08 (0.76–1.52) 0.671
2017 0.92 (0.47–1.80) 0.8
BASELINE CD4
<100 Reference Reference
100–199 1.83 (1.22–2.74) 0.003 1.95 (1.28–2.97) 0.002
200–349 1.29 (0.87–1.90) 0.201 1.45 (0.96–2.19) 0.074
350–499 1.32 (0.88–1.99) 0.183 1.52 (0.98–2.37) 0.063
≥500 1.62 (1.05–2.49) 0.029 1.81 (1.12–2.91) 0.014
HEALTH FACILITY
Agincourt Reference Reference
Belfast 2.42 (1.66–3.52) <0.001 1.97 (1.30–2.97) 0.001
Cunningmore 2.01 (1.16–3.49) 0.013 1.64 (0.91–2.96) 0.101
Justicia 2.25 (1.46–3.47) <0.001 1.96 (1.21–3.17) 0.006
Kildare 1.74 (1.12–2.71) 0.015 1.42 (0.89–2.28) 0.14
Lillydale/Bhubezi 2.53 (1.73–3.71) <0.001 2.26 (1.50–3.41) <0.001
Thulamahashe 1.14 (0.50–2.60) 0.762 1.47 (0.64–3.36) 0.363
Xanthia 1.74 (1.01–2.98) 0.045 1.86 (1.07–3.24) 0.028
PIRL LINKAGE
Not linked Reference Reference
Linked 1.59 (1.10–2.29) 0.014 2.09 (1.41–3.10) <0.001
TIME SINCE MISSED APPOINTMENT
<1 year Reference Reference
1–2 years 1.89 (1.44–2.46) <0.001 1.62 (1.21–2.17) 0.001
>2 years 1.58 (1.06–2.34) 0.025 1.34 (0.87–2.07) 0.181
CLINIC VISIT SCHEDULE
1 month Reference Reference
2 months 0.96 (0.72–1.28) 0.793 0.97 (0.71–1.34) 0.872
3 months 1.00 (0.64–1.57) 0.99 0.95 (0.59–1.52) 0.832
>3 months 0.19 (0.08–0.44) <0.001 0.31 (0.13–0.74) 0.009
TIME ON ART
≤3 months Reference
3–6 months 0.83 (0.57–1.20) 0.314
6–12 months 0.72 (0.51–1.01) 0.055
12–24 months 0.59 (0.42–0.83) 0.003
>24 months 0.32 (0.18–0.56) <0.001
less likely to be misclassified. Given that longer ART refill
schedules are synonymous with previous good adherence (66),
these patients accounted for 11% of the patients LTFU and
were also more likely to have re-engaged in care, a category
that contributed very little to misclassification. Patients whose
clinic record was successfully linked to an Agincourt HDSS
record in the PIRL database were more likely to be misclassified.
They were also more likely to have been resolved which could
explain this association. Health facilities were also positively
associated with misclassification, with the facilities with the
highest proportion of patients classified as LTFU in TIER.Net
being more likely to misclassify patients. Two of these clinics also
had issues with routine tracing, with one clinic not undertaking
any physical tracing at all, emphasizing an additional benefit of
routine tracing. Finally, patients who had been LTFU for a longer
duration were more likely to be classified as LTFU in TIER.Net,
more likely to have transferred to another clinic, and less likely
to have re-engaged in care which probably explains their higher
likelihood of misclassification.
This analysis has several limitations. Firstly, TIER.Net was
only consulted at a specific point in time. The cross-sectional
nature of TIER.Net outcomes means that some may have
changed, but we would have no way to ascertain this. We checked
TIER.Net 12 months after the initial record review for all patients
whose outcome after record review and tracing was still LTFU
and 85% of the outcomes had not changed. However, for patients
whose final outcome was resolved through new visit data in
the PIRL database, it is likely that their TIER.Net outcome also
changed. It is also possible that some of the patients categorized
as LTFU in TIER.Net are due to the rigidity of the system as
TIER.Net only allows for four possible outcomes; still in care,
transferred out, LTFU and deceased (11, 67, 68). It is possible
that for some patients, their outcomes were ascertained, but the
rigidity meant that they could not be recorded in the database
and may call for the inclusion of other possible outcomes in
the database. The exclusion of patients for whom an electronic
record could not be found from the multivariable analyses might
bias our findings. However, given the relatively small number we
expect that this bias is fairly small. Finally, we did not adjudicate
causes of death, so it is possible that patients died from causes
other than those related to HIV/AIDS. A strength of this study
is that we attempted to trace all patients that were LTFU and not
a sample. Therefore, the findings might be more generalizable to
other settings. The multiple methods, data sources and levels of
follow-up used to trace patients are also a strength.
In conclusion, although TIER.Net misclassified 36% of patient
outcomes, this reflects the various challenges with the processes
and upstream factors that lead to this misclassification and calls
for their improvement rather than the utility of the database itself,
as patients classified as LTFU were most likely to be misclassified.
Clinics should consider training staff about ascertaining patient
outcomes, putting more emphasis into patient tracing and
using other data sources such as the national death register to
improve ascertainment of patient treatment outcomes. For policy
and planning purposes, programme evaluators should consider
using correction factors to improve the accuracy of estimates
from TIER.Net.
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